康希诺生物股份公司2025年第三季度报告
Shang Hai Zheng Quan Bao·2025-10-28 00:17

Core Points - The company has announced the cancellation of its supervisory board and the revision of its articles of association, which will be submitted for shareholder approval [8][10][11] - The board of directors and senior management have guaranteed the accuracy and completeness of the quarterly report, taking legal responsibility for any misrepresentation [2][9] - The financial statements for the third quarter of 2025 are unaudited, and the company has not reported any significant non-recurring gains or losses [3][4][8] Financial Data - The financial data presented in the quarterly report is in Chinese Yuan (RMB) and covers the period from January to September 2025 [3][8] - The company has not reported any net profit from mergers under common control for the current or previous periods [8] Governance Changes - The supervisory board will be replaced by the audit committee of the board of directors, which will assume the supervisory functions as per the Company Law [8][10] - The company plans to revise its governance documents, including the articles of association and rules for shareholder and board meetings, to align with the cancellation of the supervisory board [10][11] Compliance and Legal Framework - The changes are in accordance with the Company Law and relevant regulations, ensuring compliance with the latest legal requirements [10][11] - The company will continue to fulfill its supervisory responsibilities until the cancellation of the supervisory board is approved by the shareholders [9]